Royalty Pharma plc (RPRX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Royalty Pharma plc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Royalty Pharma plc (RPRX) has returned 24.80% so far this year and 57.76% over the past 12 months.

Based on dividend-adjusted daily data since Jun 16, 2020, RPRX's average daily return is +0.03%, while the average monthly return is +0.51%. At this rate, your investment would double in approximately 11.4 years.

Historically, 51% of months were positive and 49% were negative. The best month was Jan 2025 with a return of +23.8%, while the worst month was Oct 2020 at -12.8%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 4 months.

On a daily basis, RPRX closed higher 50% of trading days. The best single day was Jan 10, 2025 with a return of +12.6%, while the worst single day was Jul 13, 2020 at -7.5%.

Royalty Pharma plc has an annualized alpha of -0.18%, beta of 0.52, and R² of 0.10 versus S&P 500 Index. Calculated based on daily prices since June 17, 2020.

• This stock participated in 56.99% of S&P 500 Index downside but only 35.61% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.52 may look defensive, but with R² of 0.10 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.10 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

RPRX ranks 94 for risk / return — in the top 94% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Royalty Pharma plc (RPRX) and compare them to a chosen benchmark (S&P 500 Index).

Royalty Pharma plc provided a 1.87% dividend yield over the last twelve months, with an annual payout of $0.90 per share. The company has been increasing its dividends for 5 consecutive years.

The table displays the monthly dividend distributions for Royalty Pharma plc. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Royalty Pharma plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Royalty Pharma plc was 49.68%, occurring on Dec 19, 2024. Recovery took 297 trading sessions.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Royalty Pharma plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Royalty Pharma plc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.